New hope for histoplasmosis: shorter, stronger drug regimens under trial
NCT ID NCT07261150
First seen Jan 05, 2026 · Last updated May 06, 2026 · Updated 14 times
Summary
This study tests whether a single high dose of an antifungal drug works better than the standard daily dose for hospitalized adults with moderate to severe histoplasmosis. It also compares a newer oral drug to the standard one, and checks if 6 months of treatment is as good as 12 months for people with HIV. The goal is to find safer, more effective ways to treat this serious infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HISTOPLASMOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Universidade Federal de Ciências da Saúde de Porto Alegre
Porto Alegre, Brazil
Contact Email: •••••@•••••
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.